First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [1] Advances in the treatment of KRASG12C mutant non-small cell lung cancer
    Shaverdashvili, Khvaramze
    Burns, Timothy F.
    CANCER, 2025, 131
  • [2] Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Chour, Ali
    Toffart, Anne-Claire
    Berton, Elodie
    Duruisseaux, Michael
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [3] Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
    Luo, Faustine X.
    Arter, Zhaohui Liao
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 161 - 167
  • [4] An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations
    Strohbehn, Garth W.
    Sankar, Kamya
    Qin, Angel
    Kalemkerian, Gregory P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (14) : 1569 - 1575
  • [5] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] KRASG12C G12C Inhibitors in Non-Small Cell Lung Cancer: A Review
    Tang, Min
    Wu, Yijun
    Bai, Xiufeng
    Lu, You
    ONCOTARGETS AND THERAPY, 2024, 17 : 683 - 695
  • [7] Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
    Zhang, Shannon S.
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 115 - 122
  • [8] KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer
    Cai, Chang
    Yao, Shuo
    Zou, Yanmei
    Lu, Hui
    Chen, Xiuqiong
    Wang, Yali
    Zheng, Kun
    Zhu, Feng
    Wang, Yihua
    Xiong, Hua
    Zhu, Junfei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (12) : 1637 - 1652
  • [9] Activity and resistance to KRASG12C G12C inhibitors in non-small cell lung cancer and colorectal cancer
    Ye, Wei
    Lu, Xin
    Qiao, Yue
    Ou, Wen-Bin
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (03):
  • [10] Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis
    Luo, Wei
    Zhu, Jing
    Zhang, Wenxue
    Yu, Airu
    Zhou, Wei
    Xu, Ke
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1295 - 1303
12345